This study has 8 locations in USA - 11 Dec `20Evaluation of AMG 714 for Vitiligo (REVEAL)

Official title: Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

The AMG 714 for Vitiligo (REVEAL Trial), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is a Phase 2 clinical study evaluating the efficacy and safety of AMG 714, an anti-IL-15 monoclonal antibody, in adults with vitiligo. The trial aims to determine if AMG 714, combined with narrowband ultraviolet B (nbUVB) phototherapy, can effectively restore skin pigmentation by modulating the immune response responsible for melanocyte destruction.

This is an active study which is not recruiting new patients.

 

Start date: 2020-12-11

Completion date: 2025-05-30

Contact: Brett A. King, MD, PhD

Tel.:

Email:

Link: https://clinicaltrials.gov/study/NCT04338581

Clinical Trials Alerts

Sign up and be the first to know when new trials are starting nearby.



FAQOther Questions

  • How smoking affects vitiligo?

    Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...

  • How can I cure vitiligo?

    Currently, there is no cure for vitiligo. However, many treatments can help manage the condition by restoring skin pigmentation, halting the progression of depigmentation, and i...